Compare SWKS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWKS | ABVX |
|---|---|---|
| Founded | 1962 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.0B |
| IPO Year | 1968 | N/A |
| Metric | SWKS | ABVX |
|---|---|---|
| Price | $63.65 | $134.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 12 |
| Target Price | $81.00 | ★ $115.83 |
| AVG Volume (30 Days) | ★ 2.4M | 1.8M |
| Earning Date | 02-04-2026 | 08-11-2025 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $4,086,900,000.00 | $6,231,374.00 |
| Revenue This Year | N/A | $6.80 |
| Revenue Next Year | $5.06 | N/A |
| P/E Ratio | $20.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $47.93 | $4.77 |
| 52 Week High | $95.46 | $148.83 |
| Indicator | SWKS | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 36.57 | 57.38 |
| Support Level | $63.67 | $139.42 |
| Resistance Level | $64.52 | $147.00 |
| Average True Range (ATR) | 1.34 | 7.25 |
| MACD | -0.07 | 0.98 |
| Stochastic Oscillator | 0.58 | 63.38 |
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.